NGeneBio Co., Ltd. KRW 2.0 billion third-party rights offering, 2,000,000 shares to largest shareholder fund
NAI summary · Not investment advice
The company will issue 2,000,000 new shares at KRW 1,000 each in a KRW 2.0 billion third-party allotment to its largest shareholder fund to repay debt.
New shares · common
2,000,000 shares
Key facts
- Issue price per share
- KRW 1,000Par value applied because the reference price is below par
- Offering method
- Third-party allotment
- Debt repayment
- KRW 2.0 billion
- New share listing date
- Dec 8, 2026
- Payment date
- Nov 23, 2026
- Board resolution date
- Nov 10, 2026
- Lock-up
- Entire new shares locked up for 1 year
Commentary
AI commentary · Not investment advice
What happened
Engene Bio decided to issue 2,000,000 new common shares to raise KRW 2.0 billion. This is a third-party allotment (new shares offered to one chosen investor, not to all shareholders). The buyer is SH Healthcare Investment No. 1 Partnership. The issue price is KRW 1,000 per share, the same as the reference share price. The money will be used entirely to repay debt.
In the company's terms
Before this issue, the company had 16,086,583 common shares outstanding. The new shares add 2,000,000 common shares.
What changes for shareholders
Payment for the new shares is due on 2026.11.23. The new shares are scheduled to be listed on 2026.12.08. All the allotted shares will be under a 1-year lock-up (they cannot be sold during that time).
Earlier Material Event Report filings from this company
| Filed | Title | Key figure · Note |
|---|---|---|
| 26.11.102026.11.10 | Material Event Report | 6,000,000 shares |
Comments
No comments yet
Comments from shareholders will appear here.
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist